Cargando…

Pyroglutamation of amyloid-βx-42 (Aβx-42) followed by Aβ1–40 deposition underlies plaque polymorphism in progressing Alzheimer's disease pathology

Amyloid-β (Aβ) pathology in Alzheimer's disease (AD) is characterized by the formation of polymorphic deposits comprising diffuse and cored plaques. Because diffuse plaques are predominantly observed in cognitively unaffected, amyloid-positive (CU-AP) individuals, pathogenic conversion into cor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Michno, Wojciech, Nyström, Sofie, Wehrli, Patrick, Lashley, Tammaryn, Brinkmalm, Gunnar, Guerard, Laurent, Syvänen, Stina, Sehlin, Dag, Kaya, Ibrahim, Brinet, Dimitri, Nilsson, K. Peter R., Hammarström, Per, Blennow, Kaj, Zetterberg, Henrik, Hanrieder, Jörg
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Biochemistry and Molecular Biology 2019
Materias:	Molecular Bases of Disease
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6497931/ https://www.ncbi.nlm.nih.gov/pubmed/30814252 http://dx.doi.org/10.1074/jbc.RA118.006604

Ejemplares similares

Delineating Amyloid Plaque Associated Neuronal Sphingolipids in Transgenic Alzheimer’s Disease Mice (tgArcSwe) Using MALDI Imaging Mass Spectrometry
por: Kaya, Ibrahim, et al.
Publicado: (2016)

CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios: better diagnostic markers of Alzheimer disease
por: Janelidze, Shorena, et al.
Publicado: (2016)

Pyroglutamate-modified Aβ(3-42) affects aggregation kinetics of Aβ(1-42) by accelerating primary and secondary pathways
por: Dammers, C., et al.
Publicado: (2017)

Activity and Architecture of Pyroglutamate-Modified Amyloid-β (Aβ(pE3-42)) Pores
por: Gillman, Alan L., et al.
Publicado: (2014)

Plasma pyroglutamate‐modified amyloid beta differentiates amyloid pathology
por: Wang, Pei‐Ning, et al.
Publicado: (2020)

Solid-phase synthesis and pathological evaluation of pyroglutamate amyloid-β(3-42) peptide
por: Cho, Illhwan, et al.
Publicado: (2023)

Synergistic Effect on Neurodegeneration by N-Truncated Aβ(4−42) and Pyroglutamate Aβ(3−42) in a Mouse Model of Alzheimer's Disease
por: Lopez-Noguerola, Jose S., et al.
Publicado: (2018)

Enhanced neprilysin-mediated degradation of hippocampal Aβ42 with a somatostatin peptide that enters the brain
por: Rofo, Fadi, et al.
Publicado: (2021)

Chemometric Strategies for Sensitive Annotation and Validation of Anatomical Regions of Interest in Complex Imaging Mass Spectrometry Data
por: Wehrli, Patrick M., et al.
Publicado: (2019)

Cerebrospinal Fluid Aβ(42/40) Corresponds Better than Aβ(42) to Amyloid PET in Alzheimer’s Disease
por: Lewczuk, Piotr, et al.
Publicado: (2016)

Low Cerebrospinal Fluid Aβ(42) and Aβ(40) are Related to White Matter Lesions in Cognitively Normal Elderly
por: Skoog, Ingmar, et al.
Publicado: (2018)

Is plasma amyloid-β 1–42/1–40 a better biomarker for Alzheimer’s disease than AβX–42/X–40?
por: Klafki, Hans-Wolfgang, et al.
Publicado: (2022)

Plasma amyloid β 42/40 ratios as biomarkers for amyloid β cerebral deposition in cognitively normal individuals
por: Fandos, Noelia, et al.
Publicado: (2017)

Chemical traits of cerebral amyloid angiopathy in familial British‐, Danish‐, and non‐Alzheimerʼs dementias
por: Michno, Wojciech, et al.
Publicado: (2022)

Intramitochondrial proteostasis is directly coupled to α-synuclein and amyloid β1-42 pathologies
por: Lautenschläger, Janin, et al.
Publicado: (2020)

Preclinical effects of APOE ε4 on cerebrospinal fluid Aβ42 concentrations
por: Lautner, Ronald, et al.
Publicado: (2017)

Cerebrospinal fluid ratios with Aβ(42) predict preclinical brain β-amyloid accumulation
por: Racine, Annie M., et al.
Publicado: (2015)

Autocatalytic amplification of Alzheimer-associated Aβ42 peptide aggregation in human cerebrospinal fluid
por: Frankel, Rebecca, et al.
Publicado: (2019)

N-terminally truncated Aβ4-x proteoforms and their relevance for Alzheimer’s pathophysiology
por: Rostagno, Agueda, et al.
Publicado: (2022)

Periodontal dysbiosis associates with reduced CSF Aβ42 in cognitively normal elderly
por: Kamer, Angela R., et al.
Publicado: (2021)

Cerebral Aβ deposition precedes reduced cerebrospinal fluid and serum Aβ42/Aβ40 ratios in the App(NL−F/NL−F) knock-in mouse model of Alzheimer’s disease
por: Andersson, Emelie, et al.
Publicado: (2023)

CSF sTREM2 in delirium—relation to Alzheimer’s disease CSF biomarkers Aβ42, t-tau and p-tau
por: Henjum, Kristi, et al.
Publicado: (2018)

X-ray diffraction and electron microscopy data for amyloid formation of Aβ40 and Aβ42
por: Selivanova, Olga M., et al.
Publicado: (2016)

Systematic Aβ Analysis in Drosophila Reveals High Toxicity for the 1-42, 3-42 and 11-42 Peptides, and Emphasizes N- and C-Terminal Residues
por: Jonson, Maria, et al.
Publicado: (2015)

Abnormal CSF amyloid-β42 and tau levels in hip fracture patients without dementia
por: Oh, Esther S., et al.
Publicado: (2018)

Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease
por: Janelidze, Shorena, et al.
Publicado: (2021)

CSF Aβ42 and Aβ42/Aβ40 Ratio in Alzheimer’s Disease and Frontotemporal Dementias
por: Constantinides, Vasilios C., et al.
Publicado: (2023)

The nonlinear relationship between cerebrospinal fluid Aβ(42) and tau in preclinical Alzheimer’s disease
por: de Leon, Mony J., et al.
Publicado: (2018)

Nonphosphorylated tau slows down Aβ(1–42) aggregation, binds to Aβ(1–42) oligomers, and reduces Aβ(1–42) toxicity
por: Beeg, Marten, et al.
Publicado: (2021)

Distributions of Aβ42 and Aβ42/40 in the Cerebrospinal Fluid in View of the Probability Theory
por: Lewczuk, Piotr, et al.
Publicado: (2021)

Synergistic Association between Plasma Aβ(1–42) and p-tau in Alzheimer’s Disease but Not in Parkinson’s Disease or Frontotemporal Dementia
por: Chiu, Ming-Jang, et al.
Publicado: (2021)

Aβ(42)/Aβ(40) and Aβ(42)/Aβ(38) Ratios Are Associated with Measures of Gait Variability and Activities of Daily Living in Mild Alzheimer’s Disease: A Pilot Study
por: Koychev, Ivan, et al.
Publicado: (2018)

Amyloid-β peptide 37, 38 and 40 individually and cooperatively inhibit amyloid-β 42 aggregation
por: Braun, Gabriel A., et al.
Publicado: (2022)

Correlative Chemical Imaging and Spatial Chemometrics Delineate Alzheimer Plaque Heterogeneity at High Spatial Resolution
por: Wehrli, Patrick M., et al.
Publicado: (2023)

Effect of Race on Prediction of Brain Amyloidosis by Plasma Aβ42/Aβ40, Phosphorylated Tau, and Neurofilament Light
por: Schindler, Suzanne E., et al.
Publicado: (2022)

Cathepsin D regulates cerebral Aβ42/40 ratios via differential degradation of Aβ42 and Aβ40
por: Suire, Caitlin N., et al.
Publicado: (2020)

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease
por: Hansson, Oskar, et al.
Publicado: (2019)

Conformational Essentials Responsible for Neurotoxicity of Aβ42 Aggregates Revealed by Antibodies against Oligomeric Aβ42
por: Song, Chuli, et al.
Publicado: (2022)

CSF T-Tau/Aβ(42) Predicts White Matter Microstructure in Healthy Adults at Risk for Alzheimer’s Disease
por: Bendlin, Barbara B., et al.
Publicado: (2012)

Following spatial Aβ aggregation dynamics in evolving Alzheimer’s disease pathology by imaging stable isotope labeling kinetics
por: Michno, Wojciech, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5btdaqmjv1fmikck0mthj8lf8g